VEGF165
SIGMA/V5765 - recombinant, expressed in HEK 293 cells, suitable for cell culture
Product Type: Chemical
VEGF Pathway Research areas: Angiogenesis, Metastasis, Hypoxia, Osteogenesis, Developmental biology Disease areas: Cancer, Osteoporosis, Ischemic stroke, Inflammation, Rheumatoid Arthritis, Diabetes See also: SRP3182; SRP4363; V5765; SRP4634; SRP4364; SRP4365, SRP3184
Purity
The purity of human, recombinant VEGF165 expressed in HEK 293 cells (Cat. No. V5765) was assessed on SDS-PAGE (1 μg/lane) followed by InstantBlue™ staining (Cat. No. ISB1L). (Representative result.)
Lane +DTT: Reduced
Lane -DTT: Non-reduced
The purity of human, recombinant VEGF165 expressed in HEK 293 cells (Cat. No. V5765) was assessed on SDS-PAGE (1 μg/lane) followed by InstantBlue™ staining (Cat. No. ISB1L). (Representative result.)
Lane +DTT: Reduced
Lane -DTT: Non-reduced
Deglycosylation
Human, recombinant VEGF165 expressed in HEK 293 cells (Cat. No. V5765) (lanes 1-2) and VEGF165 expressed in E. coli (lanes 3-4) were either treated with N glycosidase F (lanes 1,3) or untreated (lanes 2,4) and separated on SDS-PAGE followed by InstantBlue™ staining (Cat. No. ISB1L). (Representative result.)
Lanes
1. HEK 293 VEGF165 + N glycosidase F
2. HEK 293 VEGF165 - N glycosidase F
3. E. coli VEGF165 + N glycosidase F
4. E. coli VEGF165 - N glycosidase F
Human, recombinant VEGF165 expressed in HEK 293 cells (Cat. No. V5765) (lanes 1-2) and VEGF165 expressed in E. coli (lanes 3-4) were either treated with N glycosidase F (lanes 1,3) or untreated (lanes 2,4) and separated on SDS-PAGE followed by InstantBlue™ staining (Cat. No. ISB1L). (Representative result.)
Lanes
1. HEK 293 VEGF165 + N glycosidase F
2. HEK 293 VEGF165 - N glycosidase F
3. E. coli VEGF165 + N glycosidase F
4. E. coli VEGF165 - N glycosidase F
Bioassay The biological activity of human, recombinant VEGF165 expressed in HEK293 cells (Cat. No. V5765) versus control VEGF165 from E. coli was measured in a cell proliferation assay using HUVEC cells. The EC50 is defined as the effective concentration that elicits a 50% increase in cell growth in a cell-based bioassay. (Representative result.)
| assay | ≥95% (SDS-PAGE) |
| biological source | human |
| color | white |
| description | Vascular Endothelial Growth Factor 165 human |
| form | lyophilized powder |
| impurities | <0.075 EU/μg |
| mol wt | dimer 42 kDa (glycosylated) |
| packaging | pkg of 10 μg |
| pkg of 50 μg | |
| potency | <10 ng/mL ED50 |
| quality | endotoxin tested |
| Quality Level | 200  |
| recombinant | expressed in HEK 293 cells |
| solubility | water: soluble |
| storage temp. | −20°C |
| technique(s) | cell culture | mammalian: suitable |
| UniProt accession no. | P15692  |
| Analysis Note: | The specific activity was determined by the dose-dependent stimulation of the proliferation of HUVEC cells (human umbilical vein endothelial cells). |
| Biochem/physiol Actions: | VEGF165 belongs to the PDGF/VEGF growth factor family characterized by the presence of eight conserved cysteine residues and a cystine knot structure. VEGF is secreted by the majority of tumor cells and initiates angiogenesis by activating endothelial cells of existing blood vessels and promoting their migration. VEGF has also been implicated in correlation with poor prognosis in breast cancer. In addition, VEGF is released in rheumatoid arthritis in response to TNF-α, increasing endothelial permeability and stimulating angiogenesis (formation of capillaries). |
| General description: | VEGF165 is expressed in human HEK 293 cells as a glycosylated homodimer with an apparent molecular mass of 45 kDa. Production in human HEK 293 cells offers authentic glycosylation. Glycosylation contributes to stability in cell growth media and other applications. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |